Loading stock…

Bio-Rad Laboratories, Inc. (BIO) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Bio-Rad Laboratories, Inc.

BIOMarket cap $9.82BPrice $367.9

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes diagnostic testing equipment and life science research tools used in hospitals and labs worldwide. Also holds a massive, quietly valuable stake in Sartorius, a German biotech supplier, worth billions on its own balance sheet.

In Bastion Portfolios?

52W Return+19%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-3%2

Revenue Forecast

Rev CAGR (1y)-0%2

Rev CAGR (3y)+1%2

Rev CAGR (5y)+2%2

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2-1%3

EPS Growth Y+3+2%4

Quality

Margins

EBIT Margin11%5

Net Income Margin9%5

Free Cash Flow Margin14%7

Debt

Net Debt/EBITDA-0.510

Efficiency

ROE3%2

ROA2%4

Earnings Stability44

GEAR+VERY WEAK15

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)332

P/E Ratio (Forward 3y)391

P/BV1.48

EV Multiples

EV/EBITDA Fwd106

EV/EBIT Fwd137

Yield

Free Cash Flow Yield3.6%5

Dividend Yieldna–

Momentum

Short term

1 month return-3%6

3 month return+30%10

YTD return+21%8

Mid term

Price vs 52wHigh93%9

1 year return+21%7

Long term

3 year return+3%3

5 year return-49%1

Risk Shield

Price Risk

Beta0.85

Volatility37%5

Free Cash Flow

Free Cash Flow Margin14%7

Free Cash Flow Yield3.6%5

Quality

ROCE3%2

Earnings Stability44

Net Debt/EBITDA-0.510

02Growth

Is it actually growing, and how fast?

BIOBio-Rad Laboratories

Revenue FY25$2.6B

GROWTH RATING↗

VERY WEAK7 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR+1%2

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-1%3

EPS growth, FY28E+2%4

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 0.9%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 93% of companies worldwide.

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 0.9%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 0.9%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+30%10

YTD return+21%8

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+21%7

3-year return+3%3

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 21% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+30%) and so far this year (+21%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+3.1% over three years and -49% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Bio-Rad Laboratories, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BIOBio-Rad Laboratories

Revenue FY25$2.6B

GROWTH RATING↗

VERY WEAK7 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR+1%2

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-1%3

EPS growth, FY28E+2%4

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 0.9%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 93% of companies worldwide.

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 0.9%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 0.9%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+30%10

YTD return+21%8

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+21%7

3-year return+3%3

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 21% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+30%) and so far this year (+21%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+3.1% over three years and -49% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Bio-Rad Laboratories, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community